Approved peptide medicines
Several peptides are approved medicines, including insulin, GLP-1 receptor agonists such as semaglutide and liraglutide, the dual agonist tirzepatide, and tesamorelin. Approval means a regulator reviewed trial data and agreed the benefit outweighs the risk for one specific use in one specific population.
Which peptides are approved medicines, what FDA approval actually certifies, and why approval is specific to an indication rather than a general endorsement.
Approval is narrow, conditional and specific. It is not a blanket statement that a molecule is safe.
Key takeaways
- Approval is granted for an indication, not for a molecule in general.
- An approved label lists who the medicine is for, what it does, and what harms were seen in trials.
- Off-label prescribing is legal and common, but it means the use was not the one reviewed.
- Approval status can change; always check the current FDA record before relying on it.
What FDA approval certifies
To approve a drug, the FDA reviews manufacturing quality, preclinical work and human clinical trials, then decides whether the demonstrated benefit outweighs the observed risk for a defined population and use. The outcome is a label: an indication, a dosing framework, contraindications, warnings and an adverse event table.
Approval is therefore a bounded statement. 'Approved' does not mean 'safe for everyone' or 'proven for every purpose people use it for'.
Peptides with approved uses
Examples of peptide medicines with regulatory approval in the United States include:
- Insulin and its analogues - diabetes.
- Semaglutide - type 2 diabetes and chronic weight management, depending on the branded product.
- Tirzepatide - a dual GIP/GLP-1 receptor agonist with approvals in type 2 diabetes and weight-related indications.
- Liraglutide - an earlier once-daily GLP-1 receptor agonist.
- Tesamorelin - a growth hormone releasing hormone analogue with a narrow HIV-related indication.
- Leuprolide, octreotide, teriparatide and others used in oncology, endocrinology and bone health.
Approved, compounded and grey market are three different things
An approved product is manufactured under regulatory oversight and carries a reviewed label. A compounded product is prepared by a pharmacy for a specific patient need and is not itself FDA-approved. A grey-market vial sold online as 'research use only' has no oversight of identity, purity or sterility.
The three often contain molecules with the same name. They do not carry the same assurance.
Checking the current record
Regulatory status moves. Indications are added, safety communications are issued, and shortage-driven allowances change. Any page - including this one - is a snapshot. The authoritative record is the FDA's own drug databases and safety communications, linked in the sources below.
Frequently asked questions
Does FDA approval mean a peptide has no risks?
No. It means a regulator judged the benefits to outweigh the known risks for a specific use. Approved medicines carry documented adverse effects, which are listed on the label precisely because they occur.
What is off-label use?
Prescribing an approved medicine for a condition, population or purpose that was not part of the approved indication. It is legal and sometimes clinically reasonable, but the evidence supporting it may be weaker than the evidence behind the approval.
Are compounded versions of approved peptides equivalent?
No. Compounded preparations are not FDA-approved products and are not reviewed for safety, efficacy or manufacturing quality in the same way.
Related on Beiing
- Compounding, quality and safety - Why compounded and approved are not interchangeable.
- Semaglutide - An approved peptide with a large published trial record.
- How Beiing rates peptide evidence - The five evidence levels used across this section.
- Peptides & Human Biology - The hub for every page in this section.
- Editorial Standards - How our content is researched and reviewed.
Sources
- FDA - Drug Approvals and Databases - U.S. Food and Drug Administration
- FDA - Human Drug Compounding - U.S. Food and Drug Administration
- ClinicalTrials.gov - U.S. National Library of Medicine
Written by Beiing Editorial Team · Editorially reviewed by Research & Regulatory Review Desk · Published · Last reviewed . Editorial and research review by Beiing writers and researchers. This is not medical or clinical review, and no clinician signs off on our content.
Educational content only - not medical advice. In a crisis, call or text 988 (US) or your local emergency number. See crisis resources.